|
80
|
299
|
7pzqA |
Oxidized form of sars-cov-2 main protease determined by xfel radiation |
|
230
|
931
|
8gwfA |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
26
|
116
|
8bzvB |
Sars-cov-2 nsp10-16 methyltransferase in complex with adenosine |
|
101
|
593
|
8gwfE |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
80
|
306
|
7pxzA |
Reduced form of sars-cov-2 main protease determined by xfel radiation |
|
53
|
187
|
8gwfB |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
23
|
78
|
8gwfC |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
16
|
113
|
8gwfG |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
85
|
302
|
7tekA |
Sars-cov-2 3clpro in complex with n-(4-(1h-pyrazol-4-yl)phenyl)-n-(3-chlorobenzyl)-2-(pyridin-3-yl)acetamide |
|
88
|
302
|
7telA |
Sars-cov-2 3clpro in complex with n-(4-(1h-imidazol-4-yl)phenyl)-n-(3-chloro-5-fluorobenzyl)-2-(isoquinolin-4-yl)acetamide |
|
36
|
181
|
8aouA |
Solution nmr structure of full-length nsp1 from sars-cov-2. |
|
85
|
301
|
8b0tA |
Sars-cov-2 main protease adduct with au(pet3)br |
|
83
|
301
|
7wo2A |
Sars-cov-2 3clpro peptidomimetic inhibitor tpm5 |
|
86
|
301
|
8b0sA |
Sars-cov-2 main protease adduct with au(nhc)cl |
|
86
|
305
|
7zqvA |
Structure of the sars-cov-2 main protease in complex with ag7404 |
|
84
|
302
|
7zqwA |
Structure of the sars-cov-1 main protease in complex with ag7404 |
|
25
|
94
|
8hdaA |
Crystal structure of ubl1 (residues 18-111) of sars-cov-2 |
|
77
|
305
|
7qkaA |
Crystal structure of sars-cov-2 main protease in complex with covalently bound gc376 |
|
230
|
931
|
8gwgA |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
53
|
187
|
8gwiB |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
44
|
187
|
8gwnB |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
16
|
113
|
8gwgG |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
16
|
113
|
8gwiG |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
112
|
593
|
8gwnE |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
82
|
298
|
7xrsA |
Crystal structure of sars-cov-2 main protease in complex with inhibitor yh-53 |
|
101
|
593
|
8gwgE |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
101
|
593
|
8gwiE |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
184
|
926
|
8gwnA |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
22
|
72
|
8gwnC |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
23
|
78
|
8gwgC |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
23
|
78
|
8gwiC |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
21
|
113
|
8gwnG |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
79
|
298
|
7ygqA |
Crystal structure of sars main protease in complex with inhibitor yh-53 |
|
230
|
931
|
8gwiA |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
53
|
187
|
8gwgB |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
81
|
299
|
7w9gA |
Complex structure of mpro with ebselen-derivative inhibitor |
|
69
|
306
|
8ey2A |
Cryo-em structure of sars-cov-2 main protease c145s in complex with n-terminal peptide |
|
24
|
116
|
8bsdB |
Sars-cov-2 nsp10-16 methyltransferase in complex with tubercidin |
|
91
|
301
|
7zv7A |
Crystal structure of sars cov-2 main protease in complex with an inhibitor 57 |
|
201
|
926
|
8gwoA |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
61
|
306
|
7zb8A |
Crystal structure of sars-cov-2 main protease (mpro) variant k61a at 2.48 a resolution |
|
82
|
305
|
7zv8A |
Crystal structure of sars cov-2 main protease in complex with an inhibitor 58 |
|
91
|
301
|
8bsdA |
Sars-cov-2 nsp10-16 methyltransferase in complex with tubercidin |
|
85
|
306
|
7zb7A |
Crystal structure of sars-cov-2 main protease (mpro) variant y54f at 1.63 a resolution |
|
63
|
306
|
7zb6A |
Crystal structure of sars-cov-2 main protease (mpro) variant c44s at 2.12 a resolution |
|
21
|
72
|
8gwoC |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
51
|
187
|
8gwoB |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
102
|
593
|
8gwoE |
A mechanism for sars-cov-2 rna capping and its inhibition by nucleotide analogue inhibitors |
|
72
|
306
|
7lcrA |
Improved feline drugs as sars-cov-2 mpro inhibitors: structure-activity studies & micellar solubilization for enhanced bioavailability |
|
238
|
927
|
7uo4A |
Sars-cov-2 replication-transcription complex bound to remdesivir triphosphate, in a pre-catalytic state |
